
  
    
      
        
        The_DT prevalence_NN of_IN asthma_NN and_CC allergy_NN has_VBZ risen_VBN in_IN all_DT industrialized_VBN countries_NNS during_IN
        recent_JJ decades_NNS ,_, and_CC there_EX is_VBZ much_JJ debate_NN about_IN exposure_NN to_TO pets_NNS in_IN early_JJ life_NN and_CC later_RB
        development_NN of_IN asthma_NN and_CC allergy_NN ._. Some_DT studies_NNS have_VBP suggested_VBN that_IN keeping_VBG pets_NNS actually_RB
        protects_VBZ against_IN later_RB allergy—i_NN ._. e_SYM ._. ,_, that_IN early_JJ exposure_NN may_MD somehow_RB modify_VB an_DT individual_NN 's_POS
        immune_JJ system_NN to_TO tolerate_VB specific_JJ antigens_NNS ._. What_WP might_MD be_VB the_DT mechanism_NN for_IN such_JJ
        protection_NN against_IN allergy_NN ?_. One_CD theory_NN of_IN how_WRB allergies_NNS arise_VBP is_VBZ that_IN an_DT imbalance_NN in_IN T_NN
        helper_NN cell_NN subtypes_NNS tips_NNS the_DT body_NN 's_POS immune_JJ response_NN towards_IN overreacting_VBG to_TO a_DT particular_JJ
        antigen_NN ._. There_EX is_VBZ some_DT evidence_NN that_IN early_JJ exposure_NN to_TO high_JJ natural_JJ levels_NNS of_IN cat_NN allergens_NNS
        can_MD prevent_VB such_PDT an_DT inappropriate_JJ immune_JJ response_NN ._. Other_JJ researchers_NNS have_VBP suggested_VBN that_IN
        normally_RB immune_JJ responses_NNS are_VBP kept_VBN under_IN control_NN by_IN another_DT group_NN of_IN T_NN cells—regulatory_NN T_NN
        cells_NNS ._. The_DT two_CD mechanisms_NNS may_MD be_VB linked_VBN ,_, since_IN exposure_NN to_TO high_JJ levels_NNS of_IN cat_NN allergens_NNS may_MD
        induce_VB regulatory_JJ T_NN cells_NNS ._.
        Various_JJ attempts_NNS to_TO modify_VB aberrant_NN immune_JJ responses_NNS to_TO specific_JJ allergens_NNS ,_, such_JJ as_IN
        those_DT to_TO cat_NN dander_NN ,_, have_VBP been_VBN made_VBN ._. Investigators_NNS have_VBP treated_VBN patients_NNS with_IN related_VBN
        molecules_NNS ,_, either_CC peptides_NNS derived_VBN from_IN the_DT allergen_NN itself_PRP ,_, or_CC much_RB smaller_JJR peptides_NNS
        produced_VBN synthetically_RB ._. Although_IN therapy_NN with_IN peptides_NNS seems_VBZ to_TO reduce_VB allergic_JJ responses_NNS ,_,
        the_DT mechanism_NN of_IN the_DT response_NN to_TO treatment_NN has_VBZ not_RB been_VBN clear_JJ ,_, in_IN particular_JJ ,_, exactly_RB which_WDT
        cells_NNS ,_, cell_NN surface_NN markers_NNS ,_, and_CC cytokines_NNS are_VBP involved_VBN in_IN modifying_VBG the_DT immune_JJ
        response_NN ._.
        In_IN a_DT paper_NN in_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, Mark_NNP Larché_NNP and_CC colleagues_NNS have_VBP attempted_VBN to_TO dissect_NN out_RP
        this_DT pathway_NN in_IN a_DT group_NN of_IN individuals_NNS with_IN asthma_NN and_CC allergy_NN to_TO cats_NNS ._. They_PRP treated_VBD the_DT
        individuals_NNS with_IN short_JJ synthetic_JJ peptides_NNS derived_VBN from_IN the_DT sequence_NN of_IN the_DT major_JJ cat_NN
        allergen_NN ,_, 
        Felis_NNP domesticus_JJ allergen_NN 1_CD ,_, and_CC then_RB measured_VBD the_DT clinical_JJ and_CC
        immunological_JJ response_NN to_TO allergen_NN ._. They_PRP found_VBD that_DT treatment_NN with_IN the_DT peptides_NNS led_VBN to_TO the_DT
        induction_NN of_IN a_DT population_NN of_IN T_NN cells_NNS that_WDT were_VBD capable_JJ of_IN suppressing_VBG the_DT proliferation_NN of_IN
        allergen-reactive_JJ T_NN cells_NNS in_IN vitro_NN ._. Peptide_NNP treatment_NN also_RB resulted_VBD in_IN increased_VBN levels_NNS of_IN
        a_DT molecule_NN called_VBD CD_NNP 5_CD on_IN the_DT surface_NN of_IN blood_NN T_NN cells—_NN CD_NNP 5_CD has_VBZ recently_RB been_VBN associated_VBN with_IN
        suppressing_VBG T_NN cell_NN sensitivity_NN to_TO stimulation_NN ._. Finally_RB ,_, the_DT authors_NNS found_VBD that_IN the_DT degree_NN
        of_IN suppression_NN was_VBD not_RB related_VBN to_TO the_DT amount_NN of_IN peptide_NN given_VBN to_TO the_DT patients_NNS ._.
        Where_WRB does_VBZ this_DT finding_VBG leave_NN patients_NNS who_WP might_MD wonder_VB about_IN exposure_NN to_TO cats_NNS and_CC the_DT
        development_NN of_IN allergy_NN ?_. The_DT simple_JJ answer_NN is_VBZ that_IN we_PRP do_VBP not_RB know_VB exactly_RB how_WRB exposure_NN to_TO
        antigen_NN triggers_VBZ either_CC an_DT immune_JJ reaction_NN or_CC tolerance_NN ._. Once_RB triggered_VBN ,_, an_DT immune_JJ reaction_NN
        to_TO a_DT cat_NN may_MD be_VB hard—though_NN not_RB impossible—to_NN reverse_NN ,_, but_CC how_WRB or_CC why_WRB a_DT specific_JJ individual_JJ
        becomes_VBZ sensitized_JJ is_VBZ as_RB yet_RB far_RB from_IN clear_JJ ._.
      
    
  
